LA JOLLA, CA—Salk scientist Tony Hunter has received a National Cancer Institute (NCI) Outstanding Investigator Award (OIA), which supports accomplished leaders in cancer research. Hunter, who is an American Cancer Society Professor, will receive more than $7,500,000 over the next seven years to further his work. According to the NCI, the award supports investigators who are providing significant contributions toward understanding cancer and developing applications that may lead to a breakthrough in cancer research.
LA JOLLA—Breast cancer is one of the most prevalent cancers, and some forms rank among the most difficult to treat. Its various types and involvement of many different cells makes targeting such tumors difficult. Now, Salk Institute researchers have used a state-of-the-art technology to profile each cell during normal breast development in order to understand what goes wrong in cancer.
LA JOLLA—Colorectal cancer is a common lethal disease, and treatment decisions are increasingly influenced by which genes are mutated within each patient. Some patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.
LA JOLLA—The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results, published in the online version of Cancer Discovery on July 26, 2019, highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC, and you can see news coverage of the story here.
LA JOLLA—Around 85 percent of lung cancers are classified as non-small-cell lung cancers, or NSCLCs. Some patients with these cancers can be treated with targeted genetic therapies, and some benefit from immunotherapies—but the vast majority of NSCLC patients have no treatment options except for chemotherapy.
LA JOLLA—Pancreatitis is an inflammation of the pancreas that accounts for 275,000 hospitalizations in the United States annually. Patients who suffer from hereditary pancreatitis have a 40 to 50 percent lifetime risk of developing pancreatic cancer.
LA JOLLA – (June 14, 2019) Diana Hargreaves, an assistant professor in Salk’s Molecular and Cell Biology Laboratory, has been named a 2019 Pew-Stewart Scholar for Cancer Research as part of a partnership between the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust. The scholars each receive $300,000 over four years to support their work focused on a better understanding of the causes, diagnosis and treatment of cancer.
LA JOLLA—Advanced pancreatic cancer is often symptomless, leading to late diagnosis only after metastases have spread throughout the body. Additionally, tumor cells are encased in a “protective shield,” a microenvironment conferring resistance to many cancer treatment drugs. Now, Salk Institute researchers, along with an international team of collaborators, have uncovered the role of a signaling protein that may be the Achilles’ heel of pancreatic cancer.
LA JOLLA—Metastatic ovarian, prostate and breast cancers are notoriously difficult to treat and often deadly. Now, Salk Institute researchers have revealed a new role for the CDK12 protein. The findings were published in the print version of Genes & Development on April 1, 2019.
LA JOLLA—As cancer death rates drop overall, doctors have noted a frightening anomaly: deaths from colorectal cancer in people under 55 appear to be creeping up. According to the American Cancer Society, deaths in this younger group increased by 1 percent between 2007 and 2016.
LA JOLLA—Just as plastic tips protect the ends of shoelaces and keep them from fraying when we tie them, molecular tips called telomeres protect the ends of chromosomes and keep them from fusing when cells continually divide and duplicate their DNA. But while losing the plastic tips may lead to messy laces, telomere loss may lead to cancer.
LA JOLLA—The metabolic protein AMPK has been described as a kind of magic bullet for health. Studies in animal models have shown that compounds that activate the protein have health-promoting effects to reverse diabetes, improve cardiovascular health, treat mitochondrial disease—even extend life span. However, how much of the effects of these compounds can be fully attributed to AMPK versus other potential targets is unknown.
LA JOLLA—Embryonic stem cells (ESCs) are the very definition of being full of potential, given that they can become any type of cell in the body. Once they start down any particular path toward a type of tissue, they lose their unlimited potential. Scientists have been trying to understand why and how this happens in order to create regenerative therapies that can, for example, coax a person’s own cells to replace damaged or diseased organs.
LA JOLLA—Long thought to suppress cancer by slowing cellular metabolism, the protein complex AMPK also seemed to help some tumors grow, confounding researchers. Now, Salk Institute researchers have solved the long-standing mystery around why AMPK can both hinder and help cancer.
LA JOLLA—The Salk Institute is honored to welcome Dannielle Engle back to Salk as an assistant professor in the Salk Cancer Center. She is currently a senior fellow at Cold Spring Harbor Laboratory in New York, where she focuses on the early detection and treatment of pancreatic cancer. Engle conducted research in the lab of Salk Professor Geoffrey Wahl for six years as part of her doctoral program at UC San Diego.
LA JOLLA—If the cell nucleus is like a bank for DNA, nuclear pores are the security doors around its perimeter. Yet more security doors aren’t necessarily better: some cancer cells contain a dramatic excess of nuclear pores.
LA JOLLA—Cancer cells often have mutations in their DNA that can give scientists clues about how the cancer started or which treatment may be most effective. Finding these mutations can be difficult, but a new method may offer more complete, comprehensive results.
LA JOLLA—A team at the Salk Institute has identified a master switch that appears to control the dynamic behavior of tumor cells that makes some aggressive cancers so difficult to treat. The gene Sox10 directly controls the growth and invasion of a significant fraction of hard-to-treat triple-negative breast cancers.
LA JOLLA—The Salk Institute announced today that it received more than $48 million from 1,100 individual donors and private grant makers in fiscal year 2018 to support the Institute’s groundbreaking science. In addition, government partners (e.g., the National Institutes of Health) provided 47 federal grants totaling more than $55 million to Salk researchers working in the areas of cancer, plant science, neuroscience, metabolism and others.
LA JOLLA—The Salk Institute announced a $2 million gift in support of its new Conquering Cancer Initiative from its current Board of Trustees Chair, Dan Lewis, and his wife, Martina Lewis. The funds will be used to advance the Salk Cancer Center’s highest research priorities, including new investigations into five of the deadliest cancers: lung, pancreatic, brain (glioblastoma), ovarian and triple-negative breast.
LA JOLLA—Only some of us have satellite TV in our homes, but all of us have satellite DNA in cells in our bodies. Working copies of satellite DNA (called satellite RNAs) are high in certain types of cancer, such as breast and ovarian. But whether they cause cancer or merely coincide with it has been unclear.
LA JOLLA—Salk Institute scientists Ronald Evans, Diana Hargreaves, Tony Hunter, Graham McVicker and Geoffrey Wahl are among the first wave of researchers to receive funding from Padres Pedal the Cause, one of one of the largest stand-alone cancer fundraising events in San Diego. The nonprofit raised $2.4 million for cancer research in November 2017, thanks to the efforts of more than 3,000 bicycle riders, sponsors, volunteers and donors.
LA JOLLA—Salk American Cancer Society Professor Tony Hunter has been awarded the 2018 Tang Prize in Biopharmaceutical Science.
LA JOLLA—Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It’s virtually impossible to observe how these tumors operate in their natural environment and animal models don’t always provide good answers.
LA JOLLA—On Friday, April 20, 2018, the Salk Institute launched a new initiative called Conquering Cancer, to harness specific and emerging scientific strategies to tackle the five deadliest cancers: pancreatic, ovarian, lung, brain (glioblastoma) and triple-negative breast.
LA JOLLA—Salk Institute scientists, together with researchers from Switzerland’s University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer. The tumor suppressor, which could be useful as a biomarker to help diagnose and monitor treatment for liver cancer, could also be relevant for other cancer types. The work appeared in print in the journal Nature on March 29, 2018, and adds to the growing body of knowledge about cellular processes that either promote or prevent cancer.
LA JOLLA—Professor Tony Hunter, who holds an American Cancer Society Professorship at the Salk Institute, has received the 2018 Pezcoller–AACR International Award for Extraordinary Achievement in Cancer Research, one of the most prestigious honors in the field of cancer research. The prize recognizes a scientist of international renown who has made a major scientific discovery in basic cancer research or who has made significant contributions to translational cancer research.
LA JOLLA—The Salk Institute, which hosts a National Cancer Institute (NCI)–designated cancer center and Indivumed GmbH, a world leading cancer research company today announce a multi-year strategic alliance to secure, preserve and analyze human cancer tissue and annotated clinical data from consenting patients around the world, enabling the most cutting-edge basic and translational research in cancer.
LA JOLLA—Salk researchers have discovered how to curb the growth of cancer cells by blocking the cells’ access to certain nutrients. The approach, detailed in a new paper published today in Nature, took advantage of knowledge on how healthy cells use a 24-hour cycle to regulate the production of nutrients and was tested on glioblastoma brain tumors in mice.
LA JOLLA—Salk Professor and HHMI Investigator Ronald Evans has been awarded $2.5 million by Stand Up To Cancer (SU2C) as part of a multi-institution team to conduct clinical studies to open up a new avenue for immunotherapy in the treatment of pancreatic cancer. While the cancer normally excludes immune T-cells, the Evans lab discovered that modified vitamin D reprograms the cancer environment in a way that may allow the Merck drug Keytruda® to invade and destroy the tumor.
LA JOLLA—Is it better to do a task quickly and make mistakes, or to do it slowly but perfectly? When it comes to deciding how to fix breaks in DNA, cells face the same choice between two major repair pathways. The decision matters, because the wrong choice could cause even more DNA damage and lead to cancer.
LA JOLLA—Salk Professor Reuben Shaw has received the National Cancer Institute (NCI) Outstanding Investigator Award (OIA), which encourages cancer research with breakthrough potential. Shaw, a member of Salk’s Molecular and Cell Biology Laboratory and holder of the William R. Brody Chair, will receive $4.2 million in direct funding over the next seven years to further his work. The award is granted, according to the NCI website, to innovative cancer researchers with outstanding records of productivity to allow them to take greater risks and be more adventurous in their research.
LA JOLLA—Stretched out, the DNA from all the cells in our body would reach Pluto. So how does each tiny cell pack a two-meter length of DNA into its nucleus, which is just one-thousandth of a millimeter across?
LA JOLLA—Salk Professor Tony Hunter, who holds an American Cancer Society Professorship, has been awarded $500,000 as part of the $1 million Royal Swedish Academy of Sciences’ inaugural Sjöberg Prize for Cancer Research for “groundbreaking studies of cellular processes that have led to the development of new and effective cancer drugs.” The prize ceremony, which is modeled after the Nobel Prize ceremony, will be held in Stockholm during the Academy’s annual meeting on March 31, 2017, in the presence of His Majesty the King and Her Majesty the Queen of Sweden.
LA JOLLA—Just as an invasive weed might need nutrient-rich soil and water to grow, many cancers rely on the right surroundings in the body to thrive. A tumor’s microenvironment—the nearby tissues, immune cells, blood vessels and extracellular matrix—has long been known to play a role in the tumor’s growth.
LA JOLLA—When a receptor on the surface of a T cell—a sentry of the human immune system—senses a single particle from a harmful intruder, it immediately kicks the cell into action, launching a larger immune response. But exactly how the signal from a single receptor, among thousands on each T cell, can be amplified to affect a whole cell has puzzled immunologists for decades.
LA JOLLA—Clodagh O’Shea, an associate professor in the Salk Institute’s Molecular and Cell Biology Laboratory, is among the first recipients of a grant from the Faculty Scholars Program, a new partnership of Howard Hughes Medical Institute (HHMI), the Bill & Melinda Gates Foundation and the Simons Foundation for early career researchers whose work shows the potential for groundbreaking contributions in their fields. O’Shea is one of 84 Faculty Scholars who will receive $100,000–$400,000 per year over five years to support their pursuit of innovative research.
Helmsley-Salk Fellow Dmitry Lyumkis has been awarded the 2016 George Palade Award by the Microscopy Society of America. The award is given for distinguished contributions to the field of microscopy and microanalysis in the life sciences of an early career scientist.
LA JOLLA—(April 25, 2016) Salk scientists have revealed how a cellular “fuel gauge” responsible for monitoring and managing cells’ energy processes also has an unexpected role in development. This critical link could help researchers better understand cancer and diabetes pathways.
LA JOLLA—Glioblastoma multiforme is a particularly deadly cancer. A person diagnosed with this type of brain tumor typically survives 15 months, if given the best care. The late Senator Ted Kennedy succumbed to this disease in just over a year.
LA JOLLA—The Salk Institute has named Professor Reuben Shaw as the new director of Salk’s National Cancer Institute-designated Cancer Center. Shaw is a member of Salk’s Molecular and Cell Biology Laboratory and the holder of the William R. Brody Chair.
LA JOLLA—Salk Professor Beverly Emerson has been named a 2015 Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society. She earned the recognition for her distinguished contributions to the understanding of the mechanisms by which genes are transcriptionally regulated and how these processes can malfunction to cause disease.
LA JOLLA, CA—The Salk Institute will co-lead a new transatlantic ‘Dream Team’ of researchers that will launch a fresh attack on pancreatic cancer, one of the deadliest forms of cancer on both sides of the Atlantic. Stand Up To Cancer (SU2C), Cancer Research UK, and The Lustgarten Foundation selected the team and will provide $12 million in funding over three years.
LA JOLLA–Every organism–from a seedling to a president–must protect its DNA at all costs, but precisely how a cell distinguishes between damage to its own DNA and the foreign DNA of an invading virus has remained a mystery.
LA JOLLA—Salk Professor Geoffrey Wahl will receive the National Cancer Institute (NCI) Outstanding Investigator Award (OIA), which encourages cancer research with breakthrough potential. Wahl, a professor in Salk’s Gene Expression Laboratory, will receive $7.9 million over a seven-year period to further his cancer research.
LA JOLLA–As a tumor grows, its cancerous cells ramp up an energy-harvesting process to support its hasty development. This process, called autophagy, is normally used by a cell to recycle damaged organelles and proteins, but is also co-opted by cancer cells to meet their increased energy and metabolic demands.
LA JOLLA–Telomeres, specialized ends of our chromosomes that dictate how long cells can continue to duplicate themselves, have long been studied for their links to the aging process and cancer. Now, a discovery at the Salk Institute shows that telomeres may be more central than previously thought to a self-destruct program in cells that prevents tumors, a function that could potentially be exploited to improve cancer therapies.
LA JOLLA–Tony Hunter, professor and director of the Salk Institute Cancer Center, in La Jolla, California, has received the BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category for “carving out the path that led to the development of a new class of successful cancer drugs.”
LA JOLLA–For decades, researchers have struggled to translate basic scientific discoveries about cancer into therapeutics that effectively–and with minimal side effects–shrink a tumor.
LA JOLLA–Scientists at the Salk Institute have discovered a powerful one-two punch for countering a common genetic mutation that often leads to drug-resistant cancers. The dual-drug therapy–with analogs already in use for other diseases–doubled the survival rate of mice with lung cancer and halted cancer in pancreatic cells.
LA JOLLA–Like a colony of bacteria or species of animals, cancer cells within a tumor must evolve to survive. A dose of chemotherapy may kill hundreds of thousands of cancer cells, for example, but a single cell with a unique mutation can survive and quickly generate a new batch of drug-resistant cells, making cancer hard to combat.
LA JOLLA–A synthetic derivative of vitamin D was found by Salk Institute researchers to collapse the barrier of cells shielding pancreatic tumors, making this seemingly impenetrable cancer much more susceptible to therapeutic drugs.
LA JOLLA—For the first time, scientists have turned human skin cells into transplantable white blood cells, soldiers of the immune system that fight infections and invaders. The work, done at the Salk Institute, could let researchers create therapies that introduce into the body new white blood cells capable of attacking diseased or cancerous cells or augmenting immune responses against other disorders.
LA JOLLA–When faced with pathogens, the immune system summons a swarm of cells made up of soldiers and peacekeepers. The peacekeeping cells tell the soldier cells to halt fighting when invaders are cleared. Without this cease-fire signal, the soldiers, known as killer T cells, continue their frenzied attack and turn on the body, causing inflammation and autoimmune disorders such as allergies, asthma, rheumatoid arthritis, multiple sclerosis and type 1 diabetes.
LA JOLLA–Salk Institute professor Tony Hunter has been awarded the 2014 Royal Medal for biological sciences by the Royal Society, a fellowship of some of the world’s most eminent scientists based in the United Kingdom.
LA JOLLA—Scientists at the Salk Institute have identified a gene responsible for stopping the movement of cancer from the lungs to other parts of the body, indicating a new way to fight one of the world’s deadliest cancers.
LA JOLLA—The ability to switch out one gene for another in a line of living stem cells has only crossed from science fiction to reality within this decade. As with any new technology, it brings with it both promise—the hope of fixing disease-causing genes in humans, for example—as well as questions and safety concerns. Now, Salk scientists have put one of those concerns to rest: using gene-editing techniques on stem cells doesn’t increase the overall occurrence of mutations in the cells. The new results were published July 3, 2014 in the journal Cell Stem Cell.
LA JOLLA—The Salk Institute is pleased to welcome a new full professor and three new assistant professors, all exceptional leaders in their respective fields. The new faculty will facilitate innovative and collaborative breakthroughs in understanding human health and disease.
LA JOLLA—Pedal the Cause, the region’s only multiday cycling fundraiser where 100 percent of the net proceeds goes to support cancer research in San Diego, today announced five research projects funded by the inaugural 2013 event. The Pedal the Cause grants offer enough support for initial experiments, which will ideally lead to grants from federal sources and to large-scale studies.
LA JOLLA—Ronald M. Evans, director of the Gene Expression Laboratory at Salk and Howard Hughes Medical Institute investigator, is one of three scientists chosen to receive $5 million in research funding as part of The Lustgarten Foundation’s new “Distinguished Scholars” program, which recognizes individuals who have made outstanding achievements in research to focus their efforts on finding a cure for pancreatic cancer.
LA JOLLA—The Salk Institute has received a $3 million gift from the Glenn Foundation for Medical Research to allow the Institute to continue conducting research to understand the biology of normal human aging and age-related diseases.
LA JOLLA—By carefully controlling the levels of two proteins, researchers at the Salk Institute have discovered how to keep mammary stem cells—those that can form breast tissue—alive and functioning in the lab. The new ability to propagate mammary stem cells is allowing them to study both breast development and the formation of breast cancers.
LA JOLLA—Scientists at the Salk Institute for Biological Studies have identified a key genetic switch linked to the development, progression and outcome of cancer, a finding that may lead to new targets for cancer therapies.
LA JOLLA—The American Academy of Arts and Sciences (AAAS) elected Salk Professor Geoffrey M. Wahl to its society, whose ranks include Nobel laureates, Pulitzer Prize recipients and Oscar winners, as well intellectual luminaries such as George Washington, Benjamin Franklin and Albert Einstein. Wahl joins 13 other Salk professors as members into the prestigious AAAS.
LA JOLLA—Reuben Shaw, a member of the Salk Institute’s Molecular and Cell Biology Laboratory and a Howard Hughes Medical Institute early career scientist, has been promoted from associate professor to full professor.
After a rigorous evaluation process by Salk senior faculty, nonresident fellows and scientific peers, the promotion was announced Friday.
LA JOLLA—Scientists at the Salk Institute have uncovered details into a surprising—and crucial—link between brain development and a gene whose mutation is tied to breast and ovarian cancer. Aside from better understanding neurological damage associated in a small percentage of people susceptible to breast cancers, the new work also helps to better understand the evolution of the brain.
LA JOLLA, CA—Highly diverse cancers share one trait: the capacity for endless cell division. Unregulated growth is due in large part to the fact that tumor cells can rebuild protective ends of their chromosomes, which are made of repeated DNA sequences and proteins. Normally, cell division halts once these structures, called telomeres, wear down. But cancer cells keep on going by deploying one of two strategies to reconstruct telomeres.
LA JOLLA, CA—Stem cells are key to the promise of regenerative medicine: the repair or replacement of injured tissues with custom grown substitutes. Essential to this process are induced pluripotent stem cells (iPSCs), which can be created from a patient’s own tissues, thus eliminating the risk of immune rejection. However, Shinya Yamanaka’s formula for iPSCs, for which he was awarded last year’s Nobel Prize, uses a strict recipe that allows for limited variations in human cells, restricting their full potential for clinical application.
LA JOLLA,CA—A team of scientists at the Salk Institute for Biological Studies has identified why disruption of a vital pathway in cell cycle control leads to the proliferation of cancer cells. Their findings on telomeres, the stretches of DNA at the ends of chromosomes that protect our genetic code and make it possible for cells to divide, suggest a potential target for preventive measures against cancer, aging and other diseases. The findings were published July 11, 2013 in Molecular Cell.
LA JOLLA,CA—Scientists studying cancer development have known about micronuclei
for some time. These erratic, small extra nuclei, which contain fragments, or whole
chromosomes that were not incorporated into daughter cells after cell division,
are associated with specific forms of cancer and are predictive of poorer prognosis.
LA JOLLA, CA—Salk scientists Beverly M. Emerson, Christopher R. Kintner, and Paul E. Sawchenko were selected as inaugural holders of new endowed chairs created through the Joan Klein Jacobs and Irwin Mark Jacobs Senior Scientist Endowed Chair Challenge. In 2008, Dr. and Mrs. Jacobs created a challenge grant to establish endowed chairs for senior scientists. For every $2 million that a donor contributes toward an endowed chair at the Institute, the Jacobses will add $1 million to achieve the $3 million funding level required to fully endow a chair for a Salk senior scientist. To date, 17 out of 20 chairs have been established.
LA JOLLA, CA—Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.
LA JOLLA, CA—Discovering that mouse hair has a circadian clock – a 24-hour cycle of growth followed by restorative repair – researchers suspect that hair loss in humans from toxic cancer radiotherapy and chemotherapy might be minimized if these treatments are given late in the day.
LA JOLLA, CA—The Salk Institute is pleased to announce the promotions of faculty members, John Reynolds to the rank of full professor and Clodagh O’Shea and Tatyana Sharpee to associate professors based on recommendations by the Salk faculty and nonresident fellows, and approved by President William R. Brody and the Institute’s Board of Trustees.
LA JOLLA, CA—The American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to accelerating scientific progress to prevent and cure cancer, has selected four Salk scientists and two of the Institute’s nonresident fellows to be inducted in its first class of the fellows of the AACR Academy.
LA JOLLA, CA—Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.
LA JOLLA, CA—The Salk Institute for Biological Studies has received a $42 million gift-the largest in the Institute’s history-to establish the Helmsley Center for Genomic Medicine (HCGM), a research center dedicated to decoding the common genetic factors underlying many complex chronic human diseases.
LA JOLLA, CA—Scientists have long believed that glioblastoma multiforme (GBM), the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. In a paper published October 18 in Science, however, researchers at the Salk Institute for Biological Studies have found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.
LA JOLLA, CA—Cold viruses generally get a bad rap—which they’ve certainly earned—but new findings by a team of scientists at the Salk Institute for Biological Studies suggest that these viruses might also be a valuable ally in the fight against cancer.
LA JOLLA, CA—The Salk Institute is pleased to announce that professors E.J. Chichilnisky, Jan Karlseder, and Kuo-Fen Lee have each been selected as the recipient of an endowed chair to honor their consistent scientific excellence and support their biological research.
LA JOLLA, CA—Scientists have known for some time that throwing off the body’s circadian rhythm can negatively affect body chemistry. In fact, workers whose sleep-wake cycles are disrupted by night shifts are more susceptible to chronic inflammatory diseases such as diabetes, obesity and cancer.
LA JOLLA, CA—A new method for rapidly solving the three-dimensional structures of a special group of proteins, known as integral membrane proteins, may speed drug discovery by providing scientists with precise targets for new therapies, according to a paper published May 20 in Nature Methods.
LA JOLLA, CA—Faculty members Reuben Shaw and Lei Wang, have been promoted to the position of Associate Professor at the Salk Institute after a rigorous evaluation process by Salk senior faculty, Non-Resident Fellows, and scientific peers. The career milestone distinguishes these two investigators as leading authorities in their respective disciplines who have made original, innovative and notable contributions to biological research.
The Salk Institute is pleased to announce that faculty members Geoffrey M. Wahl and Martyn Goulding were celebrated as the recipients of endowed chairs in recognition of their significant scientific accomplishments at a special reception on March 29. Joseph Ecker, professor in Salk’s Plant Molecular and Cellular Biology Laboratory, who was named holder of the International Council Chair in Genetics in September 2011, was also honored at the ceremony.
LA JOLLA, CA—Rapidly dividing cancer cells are skilled at patching up damage that would stop normal cells in their tracks, including wear and tear of telomeres, the protective caps at the end of each chromosome.
LA JOLLA, CA—Renato Dulbecco, M.D., Nobel Prize winner and a global leader in cancer research passed away February 19 at his home in La Jolla. Born on February 22, 1914, he was just shy of his 98th birthday.
LA JOLLA,CA—Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.
LA JOLLA, CA—Researchers at the Salk Institute have discovered a startling feature of early brain development that helps to explain how complex neuron wiring patterns are programmed using just a handful of critical genes. The findings, published in Cell, may help scientists develop new therapies for neurological disorders, such as amyotrophic lateral sclerosis (ALS), and provide insight into certain cancers.
LA JOLLA, CA—Reviving a theory first proposed in the late 1800s that the development of organs in the normal embryo and the development of cancers are related, scientists at the Salk Institute for Biological Studies have studied organ development in mice to unravel how breast cancers, and perhaps other cancers, develop in people. Their findings provide new ways to predict and personalize the diagnosis and treatment of cancer.
LA JOLLA, CA—Salk Institute scientist Ronald Evans has been selected as the recipient of the prestigious 2012 Wolf Prize in Medicine, Israel’s highest award for achievements benefiting mankind. According to the Wolf Prize jury, Evans was selected for his discovery of the gene super-family encoding nuclear receptors and elucidating the mechanism of action of this class of receptors.
WASHINGTON, DC—The National Academy of Sciences (NAS) announces the appointment of Inder M. Verma, Ph.D., as editor-in-chief of the Proceedings of the National Academy of Sciences (PNAS), the official NAS journal. He will formally assume the editorship on November 1, and the transition to the new position will occur over several weeks.